 [1m([0morchestrator-renal failure-ATENOLOL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes ATENOLOL increase or decrease the risk of renal failure?[0m
 [1m([0morchestrator-renal failure-ATENOLOL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-renal failure-ATENOLOL[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-renal failure-ATENOLOL[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does ATENOLOL increase or decrease the risk of renal failure?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-renal failure-ATENOLOL[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes ATENOLOL increase or decrease the risk of renal failure?[0m
 [1m([0morchestrator-renal failure-ATENOLOL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-renal failure-ATENOLOL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-renal failure-ATENOLOL[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes ATENOLOL increase or decrease the risk of renal failure?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does ATENOLOL increase or decrease the risk of renal failure?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"atenolol"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: ATENOLOL: dosage_and_administration: Treatment should begin with the intravenous administration of [0m[1;31m5[0m[31m mg atenolol over [0m[1;31m5[0m[31m minutes followed by another [0m[1;31m5[0m[31m mg intravenous injection [0m[1;31m10[0m[31m minutes [0m
[31mlater. Atenolol injection should be administered under carefully controlled conditions including monitoring of blood pressure, heart rate, and electrocardiogram. Dilutions of atenolol injection in [0m
[31mDextrose Injection USP, Sodium Chloride Injection USP, or Sodium Chloride and Dextrose Injection may be used. These admixtures are stable for [0m[1;31m48[0m[31m hours if they are not used immediately. In patients who[0m
[31mtolerate the full intravenous dose [0m[1;31m([0m[1;31m10[0m[31m mg[0m[1;31m)[0m[31m, atenolol tablets [0m[1;31m50[0m[31m mg should be initiated [0m[1;31m10[0m[31m minutes after the last intravenous dose followed by another [0m[1;31m50[0m[31m mg oral dose [0m[1;31m12[0m[31m hours later. Thereafter, [0m
[31matenolol can be given orally either [0m[1;31m100[0m[31m mg once daily or [0m[1;31m50[0m[31m mg twice a day for a further [0m[1;31m6[0m[31m to [0m[1;31m9[0m[31m days or until discharge from the hospital. ATENOLOL: dosage_and_administration: If bradycardia or [0m
[31mhypotension requiring treatment or any other untoward effects occur, atenolol should be discontinued [0m[1;31m([0m[31msee full prescribing information prior to initiating therapy with atenolol tablets[0m[1;31m)[0m[31m. Data from [0m
[31mother beta blocker trials suggest that if there is any question concerning the use of IV beta blocker or clinical estimate that there is a contraindication, the IV beta blocker may be eliminated and [0m
[31mpatients fulfilling the safety criteria may be given atenolol tablets [0m[1;31m50[0m[31m mg twice daily or [0m[1;31m100[0m[31m mg once a day for at least seven days [0m[1;31m([0m[31mif the IV dosing is excluded[0m[1;31m)[0m[31m. Although the demonstration of [0m
[31mefficacy of atenolol is based entirely on data from the first seven postinfarction days, data from other beta blocker trials suggest that treatment with beta blockers that are effective in the [0m
[31mpostinfarction setting may be continued for one to three years if there are no contraindications. ATENOLOL: dosage_and_administration: Atenolol is an additional treatment to standard coronary care [0m
[31munit therapy. Elderly Patients or Patients with Renal Impairment Atenolol is excreted by the kidneys; consequently dosage should be adjusted in cases of severe impairment of renal function. In [0m
[31mgeneral, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting greater frequency of decreased hepatic, renal or cardiac function, [0m
[31mand of concomitant disease or other drug therapy. Evaluation of patients with hypertension or myocardial infarction should always include assessment of renal function. Atenolol excretion would be [0m
[31mexpected to decrease with advancing age. No significant accumulation of atenolol occurs until creatinine clearance falls below [0m[1;31m35[0m[31m mL/min/[0m[1;31m1.[0m[31m73m [0m[1;31m2[0m[31m . Accumulation of atenolol and prolongation of its [0m
[31mhalf-life were studied in subjects with creatinine clearance between [0m[1;31m5[0m[31m and [0m[1;31m105[0m[31m mL/min. ATENOLOL: dosage_and_administration: Peak plasma levels were significantly increased in subjects with creatinine [0m
[31mclearances below [0m[1;31m30[0m[31m mL/min. The following maximum oral dosages are recommended for elderly, renally-impaired patients and for patients with renal impairment due to other causes: Creatinine Clearance [0m
[1;31m([0m[31mmL/min/[0m[1;31m1.[0m[31m73m [0m[1;31m2[0m[31m [0m[1;31m)[0m[31m Atenolol Elimination Half-Life [0m[1;31m([0m[31mh[0m[1;31m)[0m[31m Maximum Dosage [0m[1;31m15[0m[31m-[0m[1;31m35[0m[31m [0m[1;31m16[0m[31m-[0m[1;31m27[0m[31m [0m[1;31m50[0m[31m mg daily [0m[1;31m<[0m[1;31m15[0m[31m >[0m[1;31m27[0m[31m [0m[1;31m25[0m[31m mg daily Some renally impaired or elderly patients being treated for hypertension may require a [0m
[31mlower starting dose of atenolol: [0m[1;31m25[0m[31m mg given as one tablet a day. If this [0m[1;31m25[0m[31m mg dose is used, assessment of efficacy must be made carefully. This should include measurement of blood pressure just [0m
[31mprior to the next dose [0m[1;31m([0m[31m"trough"[0m[31m blood pressure[0m[1;31m)[0m[31m to ensure that the treatment effect is present for a full [0m[1;31m24[0m[31m hours. ATENOLOL: dosage_and_administration: Although a similar dosage reduction may be [0m
[31mconsidered for elderly and/or renally impaired patients being treated for indications other than hypertension, data are not available for these patient populations. Patients on hemodialysis should be [0m
[31mgiven [0m[1;31m25[0m[31m mg or [0m[1;31m50[0m[31m mg after each dialysis; this should be done under hospital supervision as marked falls in blood pressure can occur. Cessation of Therapy in Patients with Angina Pectoris If [0m
[31mwithdrawal of atenolol therapy is planned, it should be achieved gradually and patients should be carefully observed and advised to limit physical activity to a minimum.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m


[31mCONTENT: ATENOLOL: indications_and_usage: INDICATIONS AND USAGE Hypertension Atenolol is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk [0m
[31mof fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of [0m
[31mpharmacologic classes including atenolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, [0m
[31mantithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than [0m[1;31m1[0m[31m drug to achieve blood pressure goals. For specific advice on goals and [0m
[31mmanagement, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood [0m
[31mPressure [0m[1;31m([0m[31mJNC[0m[1;31m)[0m[31m. ATENOLOL: indications_and_usage: Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized [0m
[31mcontrolled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely[0m
[31mresponsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular [0m
[31mmortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so [0m
[31mthat even modest reductions of severe hypertension can provide substantial benefit. ATENOLOL: indications_and_usage: Relative risk reduction from blood pressure reduction is similar across populations[0m
[31mwith varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension [0m[1;31m([0m[31mfor example, patients with diabetes or hyperlipidemia[0m[1;31m)[0m[31m, and such [0m
[31mpatients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects [0m[1;31m([0m[31mas monotherapy[0m[1;31m)[0m[31m in black patients,[0m
[31mand many antihypertensive drugs have additional approved indications and effects [0m[1;31m([0m[31me.g., on angina, heart failure, or diabetic kidney disease[0m[1;31m)[0m[31m. These considerations may guide selection of therapy. [0m
[31mAtenolol may be administered with other antihypertensive agents. Angina Pectoris Due to Coronary Atherosclerosis Atenolol is indicated for the long-term management of patients with angina pectoris. [0m
[31mATENOLOL: indications_and_usage: Acute Myocardial Infarction Atenolol is indicated in the management of hemodynamically stable patients with definite or suspected acute myocardial infarction to reduce[0m
[31mcardiovascular mortality. Treatment can be initiated as soon as the patient's clinical condition allows [0m[1;31m([0m[31msee DOSAGE AND ADMINISTRATION , CONTRAINDICATIONS , and WARNINGS [0m[1;31m)[0m[31m. In general, there is no [0m
[31mbasis for treating patients like those who were excluded from the ISIS-[0m[1;31m1[0m[31m trial [0m[1;31m([0m[31mblood pressure less than [0m[1;31m100[0m[31m mm Hg systolic, heart rate less than [0m[1;31m50[0m[31m bpm[0m[1;31m)[0m[31m or have other reasons to avoid beta blockade. [0m
[31mAs noted above, some subgroups [0m[1;31m([0m[31me.g., elderly patients with systolic blood pressure below [0m[1;31m120[0m[31m mm Hg[0m[1;31m)[0m[31m seemed less likely to benefit.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m


[31mCONTENT: ATENOLOL: drug_interactions: Drug Interactions Catecholamine-depleting drugs [0m[1;31m([0m[31me.g., reserpine[0m[1;31m)[0m[31m may have an additive effect when given with beta-blocking agents. Patients treated with atenolol[0m
[31mplus a catecholamine depletor should therefore be closely observed for evidence of hypotension and/or marked bradycardia, which may produce vertigo, syncope, or postural hypotension. Calcium channel [0m
[31mblockers may also have an additive effect when given with atenolol [0m[1;31m([0m[31msee WARNINGS [0m[1;31m)[0m[31m. Disopyramide is a Type I antiarrhythmic drug with potent negative inotropic and chronotropic effects. Disopyramide [0m
[31mhas been associated with severe bradycardia, asystole and heart failure when administered with beta blockers. Amiodarone is an antiarrhythmic agent with negative chronotropic properties that may be [0m
[31madditive to those seen with beta blockers. ATENOLOL: drug_interactions: Beta blockers may exacerbate the rebound hypertension, which can follow the withdrawal of clonidine. If the two drugs are [0m
[31mcoadministered, the beta blocker should be withdrawn several days before the gradual withdrawal of clonidine. If replacing clonidine by beta blocker therapy, the introduction of beta blockers should [0m
[31mbe delayed for several days after clonidine administration has stopped. Concomitant use of prostaglandin synthase inhibiting drugs, e.g., indomethacin, may decrease the hypotensive effects of beta [0m
[31mblockers. Information on concurrent usage of atenolol and aspirin is limited. Data from several studies, i.e., TIMI-II, ISIS-[0m[1;31m2[0m[31m, currently do not suggest any clinical interaction between aspirin and [0m
[31mbeta blockers in the acute myocardial infarction setting. ATENOLOL: drug_interactions: While taking beta blockers, patients with a history of anaphylactic reaction to a variety of allergens may have a[0m
[31mmore severe reaction on repeated challenge, either accidental, diagnostic or therapeutic. Such patients may be unresponsive to the usual doses of epinephrine used to treat the allergic reaction. Both [0m
[31mdigitalis glycosides and beta blockers slow atrioventricular conduction and decrease heart rate. Concomitant use can increase the risk of bradycardia.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m


[31mCONTENT: ATENOLOL: openfda: spl_id         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m


[31mCONTENT: ATENOLOL: pharmacodynamics: Pharmacodynamics In standard animal or human pharmacological tests, beta-adrenoreceptor blocking activity of atenolol has been demonstrated by: [0m[1;31m([0m[1;31m1[0m[1;31m)[0m[31m reduction in [0m
[31mresting and exercise heart rate and cardiac output, [0m[1;31m([0m[1;31m2[0m[1;31m)[0m[31m reduction of systolic and diastolic blood pressure at rest and on exercise, [0m[1;31m([0m[1;31m3[0m[1;31m)[0m[31m inhibition of isoproterenol induced tachycardia, and [0m[1;31m([0m[1;31m4[0m[1;31m)[0m[31m [0m
[31mreduction in reflex orthostatic tachycardia. A significant beta-blocking effect of atenolol, as measured by reduction of exercise tachycardia, is apparent within one hour following oral administration[0m
[31mof a single dose. This effect is maximal at about [0m[1;31m2[0m[31m to [0m[1;31m4[0m[31m hours, and persists for at least [0m[1;31m24[0m[31m hours. Maximum reduction in exercise tachycardia occurs within [0m[1;31m5[0m[31m minutes of an intravenous dose. ATENOLOL: [0m
[31mpharmacodynamics: For both orally and intravenously administered drug, the duration of action is dose related and also bears a linear relationship to the logarithm of plasma atenolol concentration. [0m
[31mThe effect on exercise tachycardia of a single [0m[1;31m10[0m[31m mg intravenous dose is largely dissipated by [0m[1;31m12[0m[31m hours, whereas beta-blocking activity of single oral doses of [0m[1;31m50[0m[31m mg and [0m[1;31m100[0m[31m mg is still evident beyond[0m
[1;31m24[0m[31m hours following administration. However, as has been shown for all beta-blocking agents, the antihypertensive effect does not appear to be related to plasma level. In normal subjects, the beta1 [0m
[31mselectivity of atenolol has been shown by its reduced ability to reverse the beta2-mediated vasodilating effect of isoproterenol as compared to equivalent betab-locking doses of propranolol. ATENOLOL:[0m
[31mpharmacodynamics: In asthmatic patients, a dose of atenolol producing a greater effect on resting heart rate than propranolol resulted in much less increase in airway resistance. In a placebo [0m
[31mcontrolled comparison of approximately equipotent oral doses of several beta blockers, atenolol produced a significantly smaller decrease of FEV1 than nonselective beta blockers such as propranolol [0m
[31mand, unlike those agents, did not inhibit bronchodilation in response to isoproterenol. Consistent with its negative chronotropic effect due to beta blockade of the SA node, atenolol increases sinus [0m
[31mcycle length and sinus node recovery time. Conduction in the AV node is also prolonged. Atenolol is devoid of membrane stabilizing activity, and increasing the dose well beyond that producing beta [0m
[31mblockade does not further depress myocardial contractility. Several studies have demonstrated a moderate [0m[1;31m([0m[31mapproximately [0m[1;31m10[0m[31m%[0m[1;31m)[0m[31m increase in stroke volume at rest and during exercise. ATENOLOL: [0m
[31mpharmacodynamics: In controlled clinical trials, atenolol, given as a single daily oral dose, was an effective antihypertensive agent providing [0m[1;31m24[0m[31m-hour reduction of blood pressure. Atenolol has been [0m
[31mstudied in combination with thiazide-type diuretics, and the blood pressure effects of the combination are approximately additive. Atenolol is also compatible with methyldopa, hydralazine, and [0m
[31mprazosin, each combination resulting in a larger fall in blood pressure than with the single agents. The dose range of atenolol is narrow and increasing the dose beyond [0m[1;31m100[0m[31m mg once daily is not [0m
[31massociated with increased antihypertensive effect. The mechanisms of the antihypertensive effects of beta-blocking agents have not been established. ATENOLOL: pharmacodynamics: Several possible [0m
[31mmechanisms have been proposed and include: [0m[1;31m([0m[1;31m1[0m[1;31m)[0m[31m competitive antagonism of catecholamines at peripheral [0m[1;31m([0m[31mespecially cardiac[0m[1;31m)[0m[31m adrenergic neuron sites, leading to decreased cardiac output, [0m[1;31m([0m[1;31m2[0m[1;31m)[0m[31m a central [0m
[31meffect leading to reduced sympathetic outflow to the periphery, and [0m[1;31m([0m[1;31m3[0m[1;31m)[0m[31m suppression of renin activity. The results from long-term studies have not shown any diminution of the antihypertensive efficacy[0m
[31mof atenolol with prolonged use. By blocking the positive chronotropic and inotropic effects of catecholamines and by decreasing blood pressure, atenolol generally reduces the oxygen requirements of [0m
[31mthe heart at any given level of effort, making it useful for many patients in the long-term management of angina pectoris. On the other hand, atenolol can increase oxygen requirements by increasing [0m
[31mleft ventricular fiber length and end diastolic pressure, particularly in patients with heart failure. ATENOLOL: pharmacodynamics: In a multicenter clinical trial [0m[1;31m([0m[31mISIS-[0m[1;31m1[0m[1;31m)[0m[31m conducted in [0m[1;31m16[0m[31m,[0m[1;31m027[0m[31m patients[0m
[31mwith suspected myocardial infarction, patients presenting within [0m[1;31m12[0m[31m hours [0m[1;31m([0m[31mmean = [0m[1;31m5[0m[31m hours[0m[1;31m)[0m[31m after the onset of pain were randomized to either conventional therapy plus atenolol [0m[1;31m([0m[31mn = [0m[1;31m8[0m[31m,[0m[1;31m037[0m[1;31m)[0m[31m, or [0m
[31mconventional therapy alone [0m[1;31m([0m[31mn = [0m[1;31m7[0m[31m,[0m[1;31m990[0m[1;31m)[0m[31m. Patients with a heart rate of < [0m[1;31m50[0m[31m bpm or systolic blood pressure < [0m[1;31m100[0m[31m mm Hg, or with other contraindications to beta blockade were excluded. Thirty-eight [0m
[31mpercent of each group were treated within [0m[1;31m4[0m[31m hours of onset of pain. The mean time from onset of pain to entry was [0m[1;31m5.0[0m[31m Â± [0m[1;31m2.7[0m[31m hours in both groups. ATENOLOL: pharmacodynamics: Patients in the atenolol [0m
[31mgroup were to receive atenolol injection [0m[1;31m5[0m[31m to [0m[1;31m10[0m[31m mg given over [0m[1;31m5[0m[31m minutes plus atenolol tablets [0m[1;31m50[0m[31m mg every [0m[1;31m12[0m[31m hours orally on the first study day [0m[1;31m([0m[31mthe first oral dose administered about [0m[1;31m15[0m[31m minutes [0m
[31mafter the IV dose[0m[1;31m)[0m[31m followed by either atenolol tablets [0m[1;31m100[0m[31m mg once daily or atenolol tablets [0m[1;31m50[0m[31m mg twice daily on days [0m[1;31m2[0m[31m to [0m[1;31m7[0m[31m. The groups were similar in demographic and medical history [0m
[31mcharacteristics and in electrocardiographic evidence of myocardial infarction, bundle branch block, and first degree atrioventricular block at entry. During the treatment period [0m[1;31m([0m[31mdays [0m[1;31m0[0m[31m to [0m[1;31m7[0m[1;31m)[0m[31m, the [0m
[31mvascular mortality rates were [0m[1;31m3.89[0m[31m% in the atenolol group [0m[1;31m([0m[1;31m313[0m[31m deaths[0m[1;31m)[0m[31m and [0m[1;31m4.57[0m[31m% in the control group [0m[1;31m([0m[1;31m365[0m[31m deaths[0m[1;31m)[0m[31m. This absolute difference in rates, [0m[1;31m0.68[0m[31m%, is statistically significant at the P< [0m[1;31m0[0m[31m. [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m


[31mCONTENT: ATENOLOL: adverse_reactions_table: [0m[1;31m7[0m[31m%[0m[1;31m)[0m[31m  <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31malign[0m[31m=[0m[31m"left"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m" Lrule Rrule Botrule Toprule"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m>Development of Ventricular   Septal Defect  <[0m[31m/[0m[31mtd[0m[31m><td [0m
[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m" Lrule Rrule Botrule Toprule"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m>[0m[1;31m0[0m[31m  <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m" Lrule Rrule Botrule Toprule"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m>[0m[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m  <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m" Lrule [0m
[31mRrule Botrule Toprule"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m>[0m[1;31m2[0m[31m  <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m" Lrule Rrule Botrule Toprule"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m>[0m[1;31m([0m[1;31m0[0m[31m. ATENOLOL: adverse_reactions_table: [0m[1;31m9[0m[31m%[0m[1;31m)[0m[31m  <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31malign[0m[31m=[0m[31m"left"[0m[31m [0m
[31mstyleCode[0m[31m=[0m[31m" Lrule Rrule Botrule Toprule"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m>Development of Mitral   Regurgitation  <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m" Lrule Rrule Botrule Toprule"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m>[0m[1;31m0[0m[31m  <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m
[31mstyleCode[0m[31m=[0m[31m" Lrule Rrule Botrule Toprule"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m>[0m[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m  <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m" Lrule Rrule Botrule Toprule"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m>[0m[1;31m2[0m[31m  <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m" Lrule Rrule Botrule [0m
[31mToprule"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m>[0m[1;31m([0m[1;31m0[0m[31m. ATENOLOL: adverse_reactions_table: [0m[1;31m9[0m[31m%[0m[1;31m)[0m[31m  <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31malign[0m[31m=[0m[31m"left"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m" Lrule Rrule Botrule Toprule"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m>Renal Failure  <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m
[31mstyleCode[0m[31m=[0m[31m" Lrule Rrule Botrule Toprule"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m>[0m[1;31m1[0m[31m  <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m" Lrule Rrule Botrule Toprule"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m>[0m[1;31m([0m[1;31m0[0m[31m. ATENOLOL: adverse_reactions_table: [0m[1;31m4[0m[31m%[0m[1;31m)[0m[31m  <[0m[31m/[0m[31mtd[0m[31m><td [0m
[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m" Lrule Rrule Botrule Toprule"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m>[0m[1;31m0[0m[31m  <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m" Lrule Rrule Botrule Toprule"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m>[0m[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m  <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31malign[0m[31m=[0m[31m"left"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m" [0m
[31mLrule Rrule Botrule Toprule"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m>Pulmonary Emboli  <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m" Lrule Rrule Botrule Toprule"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m>[0m[1;31m3[0m[31m  <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m" Lrule Rrule Botrule [0m
[31mToprule"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m>[0m[1;31m([0m[1;31m1[0m[31m. ATENOLOL: adverse_reactions_table: [0m[1;31m2[0m[31m%[0m[1;31m)[0m[31m  <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m" Lrule Rrule Botrule Toprule"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m>[0m[1;31m0[0m[31m  <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m" Lrule Rrule [0m
[31mBotrule Toprule"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m>[0m[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m  <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><[0m[31m/[0m[31mtbody[0m[31m><[0m[31m/[0m[31mtable[0m[1;31m>[0m[31m         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m
[32mANSWER: Atenolol has been reported to cause renal failure at a very low frequency [0m[1;32m([0m[1;32m0.4[0m[32m%[0m[1;32m)[0m[32m according to the adverse reactions table in the drug label.[0m

[32mSOURCE: ATENOLOL label[0m
[32mEXTRACT_START_END: ATENOLOL: adverse_reactions_table: Renal Failure [0m[32m...[0m[32m [0m[1;32m([0m[1;32m0.4[0m[32m%[0m[1;32m)[0m[32m [0m[32m...[0m[32m [0m[1;32m([0m[1;32m0[0m[32m%[0m[1;32m)[0m
*[1m([0morchestrator-renal failure-ATENOLOL[1m)[0m [37m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mANSWER: Atenolol has been reported to cause renal failure at a very low [0m
[34mfrequency [0m[1;34m([0m[1;34m0.4[0m[34m%[0m[1;34m)[0m[34m according to the adverse reactions table in the drug label.[0m

[34mSOURCE: ATENOLOL label[0m
[34mEXTRACT_START_END: ATENOLOL: adverse_reactions_table: Renal Failure [0m[34m...[0m[34m [0m[1;34m([0m[1;34m0.4[0m[34m%[0m[1;34m)[0m[34m [0m[34m...[0m[34m [0m[1;34m([0m[1;34m0[0m[34m%[0m[1;34m)[0m
 [1m([0morchestrator-renal failure-ATENOLOL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-renal failure-ATENOLOL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-renal failure-ATENOLOL[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does ATENOLOL increase or decrease the risk of renal failure?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I asked FDAHandler whether ATENOLOL increases or decreases the risk of renal failure."[0m[32m,[0m
[32m      [0m[32m"FDAHandler reported that Atenolol has been reported to cause renal failure at a very low frequency [0m[32m([0m[32m0.4%[0m[32m)[0m[32m according to the adverse reactions table in the drug label."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"Atenolol has been reported to increase the risk of renal failure, but this occurs at a very low frequency of 0.4% according to the drug label."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-renal failure-ATENOLOL[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-renal failure-ATENOLOL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-renal failure-ATENOLOL[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-renal failure-ATENOLOL[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does ATENOLOL increase or decrease the risk of renal failure?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I asked FDAHandler whether ATENOLOL increases or decreases the risk of renal failure."[0m[34m,[0m
[34m      [0m[34m"FDAHandler reported that Atenolol has been reported to cause renal failure at a very low frequency [0m[34m([0m[34m0.4%[0m[34m)[0m[34m according to the adverse reactions table in the drug label."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"Atenolol has been reported to increase the risk of renal failure, but this occurs at a very low frequency of 0.4% according to the drug label."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does ATENOLOL increase or decrease the risk of renal failure?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I asked FDAHandler whether ATENOLOL increases or decreases the risk of renal failure.[0m
[1;31m2[0m[31m. FDAHandler reported that Atenolol has been reported to cause renal failure at a very low frequency [0m[1;31m([0m[1;31m0.4[0m[31m%[0m[1;31m)[0m[31m according to the adverse reactions table in the drug label.[0m
[31m        -----[0m
[31m        Final answer: Atenolol has been reported to increase the risk of renal failure, but this occurs at a very low frequency of [0m[1;31m0.4[0m[31m% according to the drug label.[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m"The reasoning provided is consistent with the information given by FDAHandler and aligns with medical knowledge regarding the potential side effects of medications like Atenolol. The [0m
[32mfinal answer correctly states that Atenolol has been reported to increase the risk of renal failure at a low frequency, which is a valid conclusion based on the adverse reactions data from the drug [0m
[32mlabel. No flaws are identified in the reasoning process."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-renal failure-ATENOLOL[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m"The reasoning provided is consistent with the information given by FDAHandler and aligns with medical knowledge regarding the potential side effects of medications like Atenolol. The [0m
[34mfinal answer correctly states that Atenolol has been reported to increase the risk of renal failure at a low frequency, which is a valid conclusion based on the adverse reactions data from the drug [0m
[34mlabel. No flaws are identified in the reasoning process."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-renal failure-ATENOLOL[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Feedback: The reasoning provided is consistent with the information given by FDAHandler and aligns with medical knowledge regarding the potential side effects of medications like Atenolol. The[0m
[31mfinal answer correctly states that Atenolol has been reported to increase the risk of renal failure at a low frequency, which is a valid conclusion based on the adverse reactions data from the drug [0m
[31mlabel. No flaws are identified in the reasoning process.[0m

[31m        If any flaws in the reasoning used to produce your[0m
[31m        answer were identified, you must try again.[0m
[31m        [0m
 [1m([0morchestrator-renal failure-ATENOLOL[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-renal failure-ATENOLOL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-renal failure-ATENOLOL[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m

[32mAtenolol has been reported to increase the risk of renal failure, but this occurs at a very low frequency of [0m[1;32m0.4[0m[32m% according to the drug label.[0m
